BeiGene | A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Beigene Study ID

BGB-B3227-101

ClinicalTrials.gov ID

NCT06540066

EudraCT Number

2024-514216-27-00

China Drug Trials ID

CTR20244018

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Sex: All

Age: 18 Years / N/A

No Study Documents